Niagen Bioscience (NAGE) Financials: Revenue & Earnings
NAGE$2.52+0.03 +1.00%
$199.79M
Market Cap
—
P/E
—
Forward P/E
—
Score
Niagen Bioscience (NAGE) Financials: Revenue & Earnings
NAGE price $2.52 +0.03 +1.00%
- Ticker
- NAGE
- Price
- $2.52
- Change
- +0.03 +1.00%
- Market cap ?
- $199.79M
- Beta ?
- 2.02
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
NAGE fair value $3.26. Price $2.52. Price is 23% below fair value.
Below fair value, and cheaper than usual. A larger discount than on 98% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 10.69M. Growth 11.06%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 79.13M. Net debt -61.97M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -0.01 | — | 33.71M |
| 2026-08-04 | 0.01 | 0.01 | 29.79M | 30.53M |
| 2026-05-06 | 0.07 | 0.06 | 31.47M | 31.03M |
| 2026-03-04 | 0.03 | 0.02 | 33.84M | 31.70M |
| 2025-11-04 | 0.05 | 0.01 | 33.99M | 31.10M |
| 2025-08-06 | 0.04 | 0.02 | 31.12M | 28.31M |
| 2025-05-07 | 0.04 | 0.02 | 30.48M | 27.07M |
| 2025-03-04 | 0.09 | 0.02 | 29.12M | 26.77M |
| 2024-10-31 | 0.03 | 0.01 | 25.58M | 24.03M |
| 2024-08-07 | -0.00 | -0.02 | 22.74M | 23.32M |
| 2024-05-08 | -0.01 | -0.02 | 22.15M | 23.48M |
| 2024-03-06 | 0.00 | -0.03 | 21.20M | 20.81M |
| 2023-11-08 | 0.00 | -0.03 | 19.50M | 20.30M |
| 2023-08-09 | -0.03 | -0.04 | 20.32M | 19.42M |
| 2023-05-10 | -0.03 | -0.05 | 22.56M | 19.41M |
| 2019-12-31 | -0.15 | — | 13.09M | — |
| 2019-09-30 | -0.12 | — | 12.05M | — |
| 2019-06-30 | -0.14 | — | 11.10M | — |
| 2019-03-31 | -0.15 | — | 10.05M | — |
| 2018-12-31 | -0.15 | — | 9.07M | — |
| 2018-09-30 | -0.16 | — | 8.12M | — |
| 2018-06-30 | -0.15 | — | 7.80M | — |
| 2018-03-31 | -0.15 | — | 6.57M | — |
| 2017-12-31 | -0.17 | — | 7.53M | — |
| 2017-09-30 | 0.04 | — | 6.08M | — |
| 2017-06-30 | -0.07 | — | 4.22M | — |
| 2017-03-31 | -0.05 | — | 3.37M | — |
| 2016-12-31 | -0.06 | — | 5.64M | — |
| 2016-09-30 | -0.03 | — | 3.94M | — |
| 2016-06-30 | -0.00 | — | 8.83M | — |
| 2016-03-31 | 0.01 | — | 7.33M | — |
| 2015-12-31 | -0.02 | — | 17.88M | — |
| 2015-09-30 | -0.00 | — | 6.29M | — |
| 2015-06-30 | -0.01 | — | 6.10M | — |
| 2015-03-31 | -0.03 | — | 5.26M | — |
| 2014-12-31 | -0.04 | — | 15.31M | — |
| 2014-09-30 | -0.02 | — | 4.14M | — |
| 2014-06-30 | -0.05 | — | 3.86M | — |
| 2014-03-31 | -0.05 | — | 3.07M | — |
| 2013-12-31 | -0.03 | — | 10.16M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-30 | Lopez Carlos Luis | Buy | 2.31K | $2.71 | 6.27K |
| 2026-06-30 | Pamir Ozan | Buy | 4.25K | $2.71 | 11.53K |
| 2026-06-30 | Fried Robert N | Buy | 1.11K | $2.71 | 3.00K |
| 2026-06-24 | YU Wing Tak Wendy | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Ng Wang Yu Gary | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Cohen Ann | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Patrick Kristin | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Shahbazi Hamed | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Rubin Steven D | Buy | 31.75K | $3.45 | 109.52K |
| 2026-06-24 | Jaksch Frank L Jr | Buy | 31.75K | $3.45 | 109.52K |
| 2026-04-24 | Fried Robert N | Buy | 20.00K | $2.61 | 52.20K |
| 2026-04-24 | Fried Robert N | Sell | 20.00K | $2.61 | 52.20K |
| 2026-02-19 | Lopez Carlos Luis | Buy | 41.42K | $4.94 | 204.61K |
| 2026-02-19 | Pamir Ozan | Buy | 62.13K | $4.94 | 306.93K |
| 2026-02-19 | Fried Robert N | Buy | 503.94K | $4.94 | 2.49M |
| 2025-11-14 | Pamir Ozan | Buy | 4.46K | $6.81 | 30.41K |
| 2025-11-14 | Pamir Ozan | Buy | 2.22K | $6.85 | 15.21K |
| 2025-06-24 | Shahbazi Hamed | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | YU Wing Tak Wendy | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | Patrick Kristin | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | Rubin Steven D | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | Ng Wang Yu Gary | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | Cohen Ann | Buy | 20.00K | $14.13 | 282.60K |
| 2025-06-24 | Jaksch Frank L Jr | Buy | 20.00K | $14.13 | 282.60K |
| 2025-04-09 | Fried Robert N | Buy | 66.67K | $3.30 | 220.00K |
| 2025-04-09 | Fried Robert N | Sell | 66.67K | $3.30 | 220.00K |
Institutional holders
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| No data yet. | ||||
Earnings and financials
Niagen Bioscience Inc (NAGE) trades at $2.52, with a market cap of $199.79M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn